Literature DB >> 8667865

Critical illness myopathy and neuropathy.

N Latronico1, F Fenzi, D Recupero, B Guarneri, G Tomelleri, P Tonin, G De Maria, L Antonini, N Rizzuto, A Candiani.   

Abstract

BACKGROUND: Critically ill patients may develop muscle weakness or paralysis during the course of sepsis and multiple-organ failure. We studied peripheral nerve and muscle disorders (NMD) in comatose patients.
METHOD: Comatose patients who developed paralysis associated with absent deep-tendon reflexes had electroneuromyography (ENMG) and muscle-nerve biopsy specimens taken. Onset and duration of sepsis, multiple-organ dysfunction and failure, biochemical alterations, and drugs potentially interfering with nerve-muscle function were recorded.
FINDINGS: 24 patients became quadriparetic or quadriplegic; muscle changes were found in 23. Axonal neuropathy was found in eight of 22 patients examined. All patients had prolonged sepsis and multiple-organ dysfunction, but only 14 had multiple-organ failure. Drugs such as steroids, neuromuscular-blocking agents, and aminoglycosides were not responsible for paresis, and the part played by hyperglycaemia and hypoalbuminaemia is uncertain. Attending physicians predicted a fatal outcome in all cases, although six of seven survivors fully recovered within 115-210 days from the onset of paralysis.
INTERPRETATION: Comatose patients may become completely paralysed because of NMD. The diagnosis is important to avoid unnecessary investigations and unreasonably pessimistic prognosis. ENMG is essential for the diagnosis and for planning further clinical management. Biopsy needs to be done only when it is necessary to properly classify NMD.

Entities:  

Mesh:

Year:  1996        PMID: 8667865     DOI: 10.1016/s0140-6736(96)91074-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  78 in total

1.  Evidence of neuromuscular dysfunction in the early stages of the systemic inflammatory response syndrome.

Authors:  C F Bolton
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

2.  Critical Illness Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

3.  Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both?

Authors:  Nicola Latronico
Journal:  Intensive Care Med       Date:  2003-09       Impact factor: 17.440

4.  Electromyography and nerve conduction studies in critical care: step by step in the right direction.

Authors:  Neha S Dangayach; Martin Smith; Jan Claassen
Journal:  Intensive Care Med       Date:  2015-11-17       Impact factor: 17.440

Review 5.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

Review 6.  Spontaneous breathing during veno-venous extracorporeal membrane oxygenation.

Authors:  Stefania Crotti; Nicola Bottino; Elena Spinelli
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

7.  A Randomized Trial of an Intensive Physical Therapy Program for Patients with Acute Respiratory Failure.

Authors:  Marc Moss; Amy Nordon-Craft; Dan Malone; David Van Pelt; Stephen K Frankel; Mary Laird Warner; Wendy Kriekels; Monica McNulty; Diane L Fairclough; Margaret Schenkman
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

Review 8.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

9.  Get out of bed: immobility in the neurologic ICU.

Authors:  Claire J Creutzfeldt; Catherine L Hough
Journal:  Crit Care Med       Date:  2015-04       Impact factor: 7.598

10.  Role of endotoxin in the pathogenesis of critical illness polyneuropathy.

Authors:  B Mohammadi; I Schedel; K Graf; A Teiwes; H Hecker; B Haameijer; D Scheinichen; S Piepenbrock; R Dengler; J Bufler
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.